Co-Diagnostics, Inc.
Co-Diagnostics develops, manufactures and sells reagents and PCR diagnostic tests that detect or analyze DNA and RNA for clinical laboratories and other diagnostic customers. Its products use its Co-Primers technology and include tests for infectious diseases such as COVID-19, influenza, tuberculosis, hepatitis, malaria and Zika. The company also sells mosquito-testing products under the Vector Smart brand and develops tests for genetic traits in plants and animals. In India, its joint venture CoSara manufactures and sells laboratory PCR tests under the SaraGene brand. Co-Diagnostics makes money by selling diagnostic tests and related equipment, including instruments from other manufacturers, and through grants. Its Co-Dx PCR platform combines an instrument, diagnostic test cups and a mobile application for point-of-care and at-home testing; the platform is subject to FDA review and is not available for sale. Co-Diagnostics is headquartered in Salt Lake City, Utah.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $CODX in the last 30 days.
See all $CODX insider activity →Co-Diagnostics (CODX) will release Q3 2026 earnings on Nov 12, 2026, after market close. A conference call and webcast will follow at 4:30 p.m. ET. Management, including CEO Dwight Egan, will discuss results. The company develops molecular diagnostic tests and has a proprietary platform for at-home and point-of-care testing, pending regulatory approval.
Co-Diagnostics' joint venture, CoSara, published a study showing that 12 of 20 women with HPV tested positive for serious cervical changes or cancer. The study used CoSara's SARAGENE® HPV-HR Test. Co-Diagnostics plans to host a webinar on HPV screening and will exhibit at MICROCON 2026. The company aims to expand access to molecular diagnostics in South Asia.
Co-Diagnostics (CODX) will report Q3'26 earnings on November 5. Analysts expect revenue of 169,000 USD and a loss of 1.25 USD per share. The announcement is scheduled for 7:00 AM ET.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning CODX (Co-Diagnostics, Inc.). Coverage has skewed bullish: 1 bullish, 2 neutral, and 0 bearish.
Recent CODX coverage spans corporate actions, earnings and technology.
This sets a concrete earnings timing catalyst and can drive pre-earnings positioning and volatility into Nov. 12.
The study supports clinical credibility for SARAGENE HPV-HR and may help adoption in HPV screening programs, but it is not a regulatory approval or commercial contract.
Earnings preview may cause modest price movement as investors price in the low revenue forecast.
The CDSCO submission and strong clinical performance could drive significant upside if approval is granted, while a denial would pressure the stock.
Quorum failure and the plan for a special meeting can extend the timeline for shareholder approvals, potentially increasing uncertainty around governance and any contingent corporate actions tied to those proposals.
AlphAI scores every news story that mentions CODX with an AI model for sentiment and relevance, and aggregates insider trades from Co-Diagnostics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Co-Diagnostics (CODX) will release Q3 2026 earnings on Nov 12, 2026, after market close. A conference call and webcast will follow at 4:30 p.m. ET. Management, including CEO Dwight Egan, will discuss results. The company develops molecular diagnostic tests and has a proprietary platform for at-home and point-of-care testing, pending regulatory approval.
2 min readCo-Diagnostics' joint venture, CoSara, published a study showing that 12 of 20 women with HPV tested positive for serious cervical changes or cancer. The study used CoSara's SARAGENE® HPV-HR Test. Co-Diagnostics plans to host a webinar on HPV screening and will exhibit at MICROCON 2026. The company aims to expand access to molecular diagnostics in South Asia.
4 min readCo-Diagnostics (CODX) will report Q3'26 earnings on November 5. Analysts expect revenue of 169,000 USD and a loss of 1.25 USD per share. The announcement is scheduled for 7:00 AM ET.
1 min readCo-Diagnostics' joint venture CoSara Diagnostics completed a clinical study for its tuberculosis test, reporting 97.3% sensitivity and 96.0% specificity. The test was submitted to India's CDSCO for regulatory clearance, with a commercial launch anticipated before year-end 2026. The company has also deployed mobile and cloud infrastructure in India to support the launch.
2 min readCo-Diagnostics, Inc. (CODX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. As previously disclosed, on September 3, 2026, Co-Diagnostics, Inc. (the “Company”) held its previously announced Annual Meeting of Stockholders (the “Annual Meeting”). Because a quorum was not present or represented
2 min readCo-Diagnostics secured up to $3.1M in senior secured convertible notes from J.J. Astor & Co., with $2.1M initially funded. The notes have a 1.35x factor, 30 weekly installments, and are backed by a senior-priority lien and subsidiary guarantees. The company also agreed to an ATM proceeds waterfall and a registration rights deal for resale of conversion-related shares. Maxim Group was engaged as placement agent.
1 min readCo-Diagnostics, Inc. (CODX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Senior Secured Convertible Loan Transaction with J.J. Astor & Co. On October 9, 2026, Co-Diagnostics, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with J.J. Astor & Co. (the “Lender”), pursuant to
1 min readCo-Diagnostics, Inc. (CODX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. As previously disclosed, on September 3, 2026, Co-Diagnostics, Inc. (the “Company”) held its previously announced Annual Meeting of Stockholders (the “Annual Meeting”). However, the Company did not achieve a quorum a
1 min readCodexis (CODX) partnered with a siRNA drug developer to evaluate its ECO Synthesis platform for manufacturing RNA therapies. The collaboration will compare the platform's performance with conventional methods, focusing on purity and quality. Codexis aims to advance scalable manufacturing solutions for oligonucleotide therapeutics. The stock is currently trading at $1.36, up 3.41%.
2 min readCo-Diagnostics, Inc. (CODX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. As previously announced on September 4, 2026, on September 3, 2026, Co-Diagnostics, Inc. (the “Company”) held its previously announced Annual Meeting of Stockholders (the “Annual Meeting”). However, the Company did n
1 min read
